 BASEL, Switzerland, July 20, 2021 GLOBE NEWSWIRE -- Myovant Sciences NYSE: MYOV, a healthcare company focused on redefining care for women and for men, today announced the European Commission EC has approved the marketing authorization application for RYEQO relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, with no limitation for duration of use. The EC decision is valid in all 27 member states of the European Union, as well as Iceland, Norway, and Liechtenstein. 